BioClinica mounts European expansion to push imaging and eClinical

BioClinica is making a push into Europe. The move entails the opening of new offices in London and Munich with a combined footprint of 1,400 square meters, from which it will provide image analysis and demonstrate its eClinical tools.

Newtown, PA-based BioClinica has moved quickly to expand geographically since being turned into a private company and then merged with CCBR-SYNARC last year, adding an office in Research Triangle Park, NC, and the two sites in Europe over the past four months. The European expansion represents a bet on a region that has proven to be a fruitful hunting ground for BioClinica in the past. In 2013, growth in eClinical sales in Europe outstripped all other regions.

The other factor underpinning BioClinica's willingness to invest in imaging capacity is its belief that it will play an important role in trials in booming therapeutic areas, notably oncology. "Imaging endpoints and biomarkers are becoming increasingly important as primary and secondary endpoints for demonstrating efficacy and safety in clinical trials," BioClinica CEO John Hubbard told Outsourcing-Pharma.com.

BioClinica will also use the offices as launchpads for its eClinical business. Clients and prospects will have the opportunity to view demonstrations of the tools and receive training on them at the two offices. The eClinical suite the company is pitching to clients has expanded over the past few years, in which time BioClinica has added capabilities in risk-based monitoring, supply chain planning and other fields through buyouts, partnerships and in-house R&D.

- read Outsourcing-Pharma.com's article
- check out FierceCRO's take

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.